302 related articles for article (PubMed ID: 19703994)
21. NAMPT and NAPRT1: novel polymorphisms and distribution of variants between normal tissues and tumor samples.
Duarte-Pereira S; Silva SS; Azevedo L; Castro L; Amorim A; Silva RM
Sci Rep; 2014 Sep; 4():6311. PubMed ID: 25201160
[TBL] [Abstract][Full Text] [Related]
22. Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
Santidrian AF; LeBoeuf SE; Wold ED; Ritland M; Forsyth JS; Felding BH
DNA Repair (Amst); 2014 Nov; 23():79-87. PubMed ID: 25263164
[TBL] [Abstract][Full Text] [Related]
23. Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.
Audrito V; Managò A; La Vecchia S; Zamporlini F; Vitale N; Baroni G; Cignetto S; Serra S; Bologna C; Stingi A; Arruga F; Vaisitti T; Massi D; Mandalà M; Raffaelli N; Deaglio S
J Natl Cancer Inst; 2018 Mar; 110(3):. PubMed ID: 29309612
[TBL] [Abstract][Full Text] [Related]
24. Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors.
Wilsbacher JL; Cheng M; Cheng D; Trammell SAJ; Shi Y; Guo J; Koeniger SL; Kovar PJ; He Y; Selvaraju S; Heyman HR; Sorensen BK; Clark RF; Hansen TM; Longenecker KL; Raich D; Korepanova AV; Cepa S; Towne DL; Abraham VC; Tang H; Richardson PL; McLoughlin SM; Badagnani I; Curtin ML; Michaelides MR; Maag D; Buchanan FG; Chiang GG; Gao W; Rosenberg SH; Brenner C; Tse C
Mol Cancer Ther; 2017 Jul; 16(7):1236-1245. PubMed ID: 28468779
[TBL] [Abstract][Full Text] [Related]
25. Nampt/PBEF/visfatin and cancer.
Bi TQ; Che XM
Cancer Biol Ther; 2010 Jul; 10(2):119-25. PubMed ID: 20647743
[TBL] [Abstract][Full Text] [Related]
26. Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression.
Franceschini N; Oosting J; Tamsma M; Niessen B; Bruijn IB; van den Akker B; Kruisselbrink AB; Palubeckaitė I; Bovée JVMG; Cleton-Jansen AM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200964
[TBL] [Abstract][Full Text] [Related]
27. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
[TBL] [Abstract][Full Text] [Related]
28. Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.
Nomura M; Ohuchi M; Sakamoto Y; Kudo K; Yaku K; Soga T; Sugiura Y; Morita M; Hayashi K; Miyahara S; Sato T; Yamashita Y; Ito S; Kikuchi N; Sato I; Saito R; Yaegashi N; Fukuhara T; Yamada H; Shima H; Nakayama KI; Hirao A; Kawasaki K; Arai Y; Akamatsu S; Tanuma SI; Sato T; Nakagawa T; Tanuma N
Nat Commun; 2023 Dec; 14(1):8095. PubMed ID: 38092728
[TBL] [Abstract][Full Text] [Related]
29. Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618.
Xiao Y; Elkins K; Durieux JK; Lee L; Oeh J; Yang LX; Liang X; DelNagro C; Tremayne J; Kwong M; Liederer BM; Jackson PK; Belmont LD; Sampath D; O'Brien T
Neoplasia; 2013 Oct; 15(10):1151-60. PubMed ID: 24204194
[TBL] [Abstract][Full Text] [Related]
30. NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.
Peterse EFP; van den Akker BEWM; Niessen B; Oosting J; Suijker J; de Jong Y; Danen EHJ; Cleton-Jansen AM; Bovée JVMG
Mol Cancer Res; 2017 Dec; 15(12):1714-1721. PubMed ID: 28860121
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
[TBL] [Abstract][Full Text] [Related]
32. Advances in NAD-Lowering Agents for Cancer Treatment.
Ghanem MS; Monacelli F; Nencioni A
Nutrients; 2021 May; 13(5):. PubMed ID: 34068917
[TBL] [Abstract][Full Text] [Related]
33. Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.
Tarrant JM; Dhawan P; Singh J; Zabka TS; Clarke E; DosSantos G; Dragovich PS; Sampath D; Lin T; McCray B; La N; Nguyen T; Kauss A; Dambach D; Misner DL; Diaz D; Uppal H
Toxicol Mech Methods; 2015 Mar; 25(3):201-11. PubMed ID: 25894564
[TBL] [Abstract][Full Text] [Related]
34. Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin.
Bolandghamat Pour Z; Nourbakhsh M; Mousavizadeh K; Madjd Z; Ghorbanhosseini SS; Abdolvahabi Z; Hesari Z; Ezzati Mobasser S
BMC Cancer; 2019 Nov; 19(1):1027. PubMed ID: 31675930
[TBL] [Abstract][Full Text] [Related]
35. OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis.
Korotchkina L; Kazyulkin D; Komarov PG; Polinsky A; Andrianova EL; Joshi S; Gupta M; Vujcic S; Kononov E; Toshkov I; Tian Y; Krasnov P; Chernov MV; Veith J; Antoch MP; Middlemiss S; Somers K; Lock RB; Norris MD; Henderson MJ; Haber M; Chernova OB; Gudkov AV
Leukemia; 2020 Jul; 34(7):1828-1839. PubMed ID: 31896781
[TBL] [Abstract][Full Text] [Related]
36. NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism.
Burgos ES
Curr Med Chem; 2011; 18(13):1947-61. PubMed ID: 21517777
[TBL] [Abstract][Full Text] [Related]
37. NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.
Hong SM; Park CW; Kim SW; Nam YJ; Yu JH; Shin JH; Yun CH; Im SH; Kim KT; Sung YC; Choi KY
Oncogene; 2016 Jul; 35(27):3544-54. PubMed ID: 26568303
[TBL] [Abstract][Full Text] [Related]
38. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
[TBL] [Abstract][Full Text] [Related]
39. Targeting the NAD
Ye C; Qi L; Li X; Wang J; Yu J; Zhou B; Guo C; Chen J; Zheng S
Cell Commun Signal; 2020 Jan; 18(1):16. PubMed ID: 32005247
[TBL] [Abstract][Full Text] [Related]
40. An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma.
Gujar AD; Le S; Mao DD; Dadey DY; Turski A; Sasaki Y; Aum D; Luo J; Dahiya S; Yuan L; Rich KM; Milbrandt J; Hallahan DE; Yano H; Tran DD; Kim AH
Proc Natl Acad Sci U S A; 2016 Dec; 113(51):E8247-E8256. PubMed ID: 27930300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
